EA033004B1 - ХЕЛПЕРЗАВИСИМЫЙ АДЕНОВИРУСНЫЙ ВЕКТОР ДЛЯ ДОСТАВКИ И ДОЛГОВРЕМЕННОЙ ЭКСПРЕССИИ АНТАГОНИСТА РЕЦЕПТОРА ИНТЕРЛЕЙКИНА-1 (Il-1Ra) И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕОАРТРИТА - Google Patents

ХЕЛПЕРЗАВИСИМЫЙ АДЕНОВИРУСНЫЙ ВЕКТОР ДЛЯ ДОСТАВКИ И ДОЛГОВРЕМЕННОЙ ЭКСПРЕССИИ АНТАГОНИСТА РЕЦЕПТОРА ИНТЕРЛЕЙКИНА-1 (Il-1Ra) И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕОАРТРИТА

Info

Publication number
EA033004B1
EA033004B1 EA201491457A EA201491457A EA033004B1 EA 033004 B1 EA033004 B1 EA 033004B1 EA 201491457 A EA201491457 A EA 201491457A EA 201491457 A EA201491457 A EA 201491457A EA 033004 B1 EA033004 B1 EA 033004B1
Authority
EA
Eurasian Patent Office
Prior art keywords
osteoarthritis
helper
prevention
treatment
mammalian
Prior art date
Application number
EA201491457A
Other languages
English (en)
Other versions
EA201491457A1 (ru
Inventor
Брендан Ли
Килиан Гузе
Чжечао Жуань
Original Assignee
Байлор Колледж Оф Медсин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байлор Колледж Оф Медсин filed Critical Байлор Колледж Оф Медсин
Publication of EA201491457A1 publication Critical patent/EA201491457A1/ru
Publication of EA033004B1 publication Critical patent/EA033004B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к фармацевтической композиции для лечения и профилактики остеоартрита, содержащей хелперзависимый аденовирусный вектор для доставки и долговременной экспрессии антагониста рецептора интерлейкина-1 (Il-1Ra) в синовиальных клетках в суставах млекопитающего, причем вектор содержит последовательность нуклеотидов, кодирующую антагонисты Il-1Ra человека или млекопитающего животного, левые и правые инвертированные концевые повторы (L ITR и R ITR), сигнал упаковки аденовируса и невирусные некодирующие спейсерные последовательности нуклеотидов, где экспрессия гена Il-1Ra человека или млекопитающего животного регулируется промотором, который индуцируется иммуностимулирующими веществами при воспалении и расположен перед рамкой считывания последовательности нуклеотидов, кодирующей Il-1Ra человека или млекопитающего животного. Изобретение также относится к применению хелперзависимого аденовирусного вектора для лечения или профилактики остеоартрита.
EA201491457A 2012-02-02 2013-01-23 ХЕЛПЕРЗАВИСИМЫЙ АДЕНОВИРУСНЫЙ ВЕКТОР ДЛЯ ДОСТАВКИ И ДОЛГОВРЕМЕННОЙ ЭКСПРЕССИИ АНТАГОНИСТА РЕЦЕПТОРА ИНТЕРЛЕЙКИНА-1 (Il-1Ra) И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕОАРТРИТА EA033004B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120000703 EP2623604B8 (en) 2012-02-02 2012-02-02 Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
PCT/IB2013/000198 WO2013114199A1 (en) 2012-02-02 2013-01-23 Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis

Publications (2)

Publication Number Publication Date
EA201491457A1 EA201491457A1 (ru) 2014-11-28
EA033004B1 true EA033004B1 (ru) 2019-08-30

Family

ID=47891791

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491457A EA033004B1 (ru) 2012-02-02 2013-01-23 ХЕЛПЕРЗАВИСИМЫЙ АДЕНОВИРУСНЫЙ ВЕКТОР ДЛЯ ДОСТАВКИ И ДОЛГОВРЕМЕННОЙ ЭКСПРЕССИИ АНТАГОНИСТА РЕЦЕПТОРА ИНТЕРЛЕЙКИНА-1 (Il-1Ra) И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕОАРТРИТА

Country Status (12)

Country Link
US (4) US10301647B2 (ru)
EP (1) EP2623604B8 (ru)
JP (2) JP6340320B2 (ru)
CN (1) CN104245941B (ru)
AU (1) AU2013213873B2 (ru)
CA (1) CA2861408C (ru)
DK (1) DK2623604T3 (ru)
EA (1) EA033004B1 (ru)
ES (1) ES2534782T3 (ru)
IN (1) IN2014KN01682A (ru)
PL (1) PL2623604T3 (ru)
WO (1) WO2013114199A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361452A1 (en) 2013-01-25 2015-12-17 Baylor College Of Medicine A Helper-Dependent Adenoviral Gene Therapy Delivery and Expression System
GB201410314D0 (en) * 2014-06-10 2014-07-23 Advanced Risc Mach Ltd Display controller
SG11201707025WA (en) * 2015-03-02 2017-09-28 Synlogic Inc Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
MX2018008651A (es) 2016-01-13 2019-03-14 Merial Inc Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
WO2018035451A1 (en) 2016-08-19 2018-02-22 Calimmune, Inc. Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
US11529393B2 (en) 2016-10-10 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use
WO2018106956A2 (en) * 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated IL-1RA CDNAs
KR20190138311A (ko) 2017-04-21 2019-12-12 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법
WO2021055860A1 (en) * 2019-09-18 2021-03-25 Flexion Therapeutics, Inc. Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same
JPWO2022234844A1 (ru) * 2021-05-06 2022-11-10
CN118159302A (zh) * 2021-08-24 2024-06-07 帕西拉制药有限公司 用于椎间盘退变的IL-1Ra基因疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747072A (en) 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
US20030091536A1 (en) 1999-09-07 2003-05-15 Colorado State University Research Foundation In vivo treatment of joint disease using interleukin-1
FR2806418B1 (fr) * 2000-03-14 2004-07-16 Aventis Pharma Sa Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations
AU2002311777A1 (en) 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
ES2827247T3 (es) * 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
CA2760608A1 (en) * 2009-05-01 2010-11-04 Oregon Health & Science University Method of expanding human hepatocytes in vivo
US20100316651A1 (en) * 2009-05-29 2010-12-16 Xoma Technology Ltd. Cardiovascular related uses of il-1beta antibodies and binding fragments thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. C. BAKKER, F. A. J. VAN DE LOO, L. A. B. JOOSTEN, O. J. ARNTZ, A. W. VARLEY, R. S. MUNFORD, W. B. VAN DEN BERG: "C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene.", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 46, no. 6, 1 June 2002 (2002-06-01), US, pages 1661 - 1670, XP002675514, ISSN: 0004-3591, DOI: 10.1002/ART.10481 *
GABRIELE TOIETTA, LUCIO PASTORE, VINCENZO CERULLO, MILTON FINEGOLD, ARTHUR L. BEAUDET, BRENDAN LEE: "Generation of helper-dependent adenoviral vectors by homologous recombination.", MOLECULAR THERAPY, vol. 5, no. 2, 1 February 2002 (2002-02-01), pages 204 - 210, XP002675516, ISSN: 1525-0016, DOI: 10.1006/MTHE.2002.0532 *
KHOURY M, ET AL: "Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis.", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 9, no. 7, 1 January 2007 (2007-01-01), US, pages 596 - 604, XP002675517, ISSN: 1099-498X, DOI: 10.1002/JGM.1053 *
PALMER DONNA, NG PHILIP: "Improved system for helper-dependent adenoviral vector production.", MOLECULAR THERAPY, vol. 8, no. 5, 1 November 2003 (2003-11-01), pages 846 - 852, XP002675515, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2003.08.014 *

Also Published As

Publication number Publication date
PL2623604T3 (pl) 2015-07-31
EP2623604B8 (en) 2015-04-22
JP6340320B2 (ja) 2018-06-06
US20150031083A1 (en) 2015-01-29
JP2015506695A (ja) 2015-03-05
AU2013213873B2 (en) 2018-06-21
ES2534782T3 (es) 2015-04-28
JP2018075035A (ja) 2018-05-17
CN104245941B (zh) 2016-12-07
EA201491457A1 (ru) 2014-11-28
IN2014KN01682A (ru) 2015-10-23
US20220073948A1 (en) 2022-03-10
AU2013213873A1 (en) 2014-09-25
EP2623604A1 (en) 2013-08-07
WO2013114199A8 (en) 2014-09-25
CA2861408A1 (en) 2013-08-08
US10301647B2 (en) 2019-05-28
DK2623604T3 (da) 2015-06-01
CN104245941A (zh) 2014-12-24
EP2623604B1 (en) 2015-02-25
US20220348963A1 (en) 2022-11-03
CA2861408C (en) 2021-10-26
US20190376080A1 (en) 2019-12-12
WO2013114199A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
EA033004B1 (ru) ХЕЛПЕРЗАВИСИМЫЙ АДЕНОВИРУСНЫЙ ВЕКТОР ДЛЯ ДОСТАВКИ И ДОЛГОВРЕМЕННОЙ ЭКСПРЕССИИ АНТАГОНИСТА РЕЦЕПТОРА ИНТЕРЛЕЙКИНА-1 (Il-1Ra) И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕОАРТРИТА
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MY162737A (en) 4-1bb binding molecules
MX2020012742A (es) Metodo y composiciones para inmunoterapia celular.
MX2020012240A (es) Agentes de ligacion agonistas del receptor tnf.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
WO2011028344A3 (en) Interleukin-1 receptor antagonist compositions and methods of making and using same
MX2015014423A (es) Administración efectiva de genes grandes por vectores aav duales.
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
MX359258B (es) Polipeptidos de enlace biparatopicos para cxcr2 y usos de los mismos.
MX2013005186A (es) Polipeptidos que se enlazan a cxcr2.
PH12015500771A1 (en) Novel fc gamma receptor iib variants
MX2013010392A (es) Proteinas de fusion npp1.
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
TN2013000171A1 (en) Cxcr2 binding polypeptides
MX2014010873A (es) Lotes de adenovirus recombinantes con extremos alterados.
UA99801C2 (ru) Белковая конструкция, которая включает модифицированный полипептид casb7439